免疫吸附治疗强直性脊柱炎疗效观察

The efficacy of immunoabsorption therapy for ankylosing spondylitis

目的 观察免疫吸附治疗强直性脊柱炎(ankylosing spondylitis,AS)的疗效.方法 选取AS常规治疗组30例和AS免疫吸附治疗组30例为实验对象,分别于治疗前、治疗后1周、1月、3月后检测3组红细胞沉降率(erythrocyte sedimentation rate,ESR)、C反应蛋白(C-reaction protein,CRP),并评估Bath AS疾病活动指数评分(Bath AS disease activity index,BASDAI). 结果 ①免疫吸附治疗1周治疗组患者较对照组ESR、CRP、BASDAI的差异有统计学意义(Z值分别为2.692,2.511,3.866;P值分别为-0.007,0.012,<0.001).②免疫吸附治疗3月后免疫吸附治疗组较对照组ESR、CRP下降,BAS-DAI评分降低,差异有统计学意义(Z值分别为2.905,6.427,2.000;P值分别为0.004,<0.001,0.045);③治疗3月后免疫吸附治疗组较对照组非甾体类抗炎药的用量下降,差异有统计学意义(Z=4.296,P<0.001). 结论 免疫吸附治疗AS,炎症指标恢复快,起效快,病情易于稳定.免疫吸附治疗可减轻炎症反应.

Objective To investigate the efficacy of immunoadsorption therapy for ankylosing spondylitis(AS).Methods A total of 60 patients with AS were recruited and allocated into control group(n=30)or immunoadsorption group(n=30).Erythrocyte sedimentation rate(ESR),C-reaction protein(CRP)and the score of Bath AS disease activity index(BASDAI)were assessed before the treatment and at the first week,first month and 3 rd month after the treatment.Results At the first week after the treatment,ESR(Z=2.692,P=-0.007),CRP(Z=2.511,P=0.012)and BASDAI score(Z=3.866,P=0.000)were significantly lower in immunoadsorption group than in control group.At the 3 rd month after the treatment,ESR(Z=2.905,P=0.004),CRP(Z=6.427,P=0.000)and BASDAI score(Z=2.000,P=0.045)were still lower in immunoadsorption group than in control group;in addition,the doses of non-steroid anti-inflammatory drugs(NSAIDs)reduced in immunoadsorption group as compared with those in control group(Z=4.296,P=0.000).Conclusion Immunoadsorption treatment for AS has the advantages of fast improvement of inflammatory biomarkers and clinical conditions with stable efficacies.Immunoadsorption therapy can also alleviate the inflammation responses in AS patients.